Press Releases April 20, 2026 04:05 PM

Regeneron Announces Investor Conference Presentations

Regeneron to Present at Major Healthcare Investor Conferences in May and June 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
REGN

Regeneron Pharmaceuticals announced its participation in upcoming investor conferences hosted by BofA Securities and Goldman Sachs. The company will webcast management presentations, providing updates on its biotechnology pipeline and strategies. Replays and transcripts will be accessible via Regeneron's investor website.

Regeneron Announces Investor Conference Presentations
REGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Regeneron will present at the BofA Securities Health Care Conference on May 12, 2026, and at Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
  • The company is a leader in biotechnology with a portfolio targeting eye, allergic, inflammatory, cancer, cardiovascular, neurological, infectious, and rare diseases.
  • Regeneron leverages proprietary technologies and data-driven insights for drug discovery and development, highlighting its sustained innovation capacity.

TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

• BofA Securities Health Care Conference 2026 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 12, 2026

• Goldman Sachs 47th Annual Global Healthcare Conference at 2:00 p.m. ET on Monday,  June 8, 2026

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier
of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
[email protected]        


Risks

  • Potential market uncertainty due to lack of new product announcements in this release, possibly limiting immediate stock movement.
  • Conference presentations may include forward-looking statements that carry inherent risks of clinical, regulatory, or commercialization delays affecting future results.
  • The biotechnology sector faces competitive pressures and regulatory challenges that can impact investor sentiment and company performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026